Sugi Predict

Sugi Predict / Compounds / SCHEMBL13456

SCHEMBL13456

SCHEMBL13456

c1cc2c(nn1)NCCC2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NNMT P40261 1/20 0.37
▸ CHRNB2 P17787 1/20 0.35
▸ CHRNA4 P43681 1/20 0.35
▸ UHRF1 Q96T88 1/20 0.35
▸ SIGMAR1 Q99720 1/20 0.34
▸ KDM4E B2RXH2 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ ITGB3 P05106 1/20 0.32
▸ ITGAV P06756 1/20 0.32
▸ CA12 O43570 1/20 0.32
▸ CA1 P00915 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ CA9 Q16790 1/20 0.32
▸ NOS3 P29474 1/20 0.31
▸ NOS1 P29475 1/20 0.31
▸ NOS2 P35228 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ TP53 P04637 1/20 0.30
▸ GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17546636 0.92 SIGMAR1 (0.36) NNMTCHRNB2CHRNA4UHRF1SIGMAR1
SCHEMBL18465423 0.92 SIGMAR1 (0.36) NNMTCHRNB2CHRNA4UHRF1SIGMAR1
SCHEMBL2561705 0.87 — —
SCHEMBL5761232 0.73 NNMT (0.39) NNMTUHRF1
SCHEMBL38950 0.71 NNMT (0.44) NNMTUHRF1KDM4EMAPT
SCHEMBL29416448 0.71 NNMT (0.44) NNMTUHRF1KDM4EMAPT
SCHEMBL29005350 0.71 — —
SCHEMBL6000727 0.69 NNMT (0.40) NNMTUHRF1ITGB3ITGAVNOS3
Hydrochloric Acid SCHEMBL21777851 0.69 NNMT (0.42) NNMTUHRF1KDM4EMAPTALDH1A1
Hydrochloric Acid SCHEMBL31063054 0.69 NNMT (0.42) NNMTUHRF1KDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 357 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630420-A1 INHIBITORS OF NLRP3 F. Hoffmann-La Roche AG (CH) 2025-10-15 — — EP disclosed
WO-2024121184-A1 INHIBITORS OF NLRP3 F. HOFFMANN-LA ROCHE AG (CH) 2024-06-13 — — WO disclosed
CN-114450284-B 6, 7-Dihydro-5H-pyrido [2,3-C ] pyridazine derivatives as BCL-XL protein inhibitors 法国施维雅药厂 2024-05-07 — — CN disclosed
CN-114450284-B 6, 7-Dihydro-5H-pyrido [2,3-C ] pyridazine derivatives as BCL-XL protein inhibitors 法国施维雅药厂 2024-05-07 — — CN disclosed
CN-114450284-B 6, 7-Dihydro-5H-pyrido [2,3-C ] pyridazine derivatives as BCL-XL protein inhibitors 法国施维雅药厂 2024-05-07 — — CN disclosed
EP-4003989-B1 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER SERVIER LAB (FR) 2023-12-27 — — EP disclosed
US-11807634-B2 Cyclopropyl dihydroquinoline sulfonamide compounds AMGEN INC. (US) 2023-11-07 — — US disclosed
US-20230234948-A1 CYCLOPROPYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS AMGEN INC. (US) 2023-07-27 — — US disclosed
US-20230227442-A1 HETEROALKYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS AMGEN INC. (US) 2023-07-20 — — US disclosed
US-20230227442-A1 HETEROALKYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS AMGEN INC. (US) 2023-07-20 — — US disclosed
US-20070142381-A1 Calcium receptor modulating agents AMGEN INC. 2007-06-21 — — US disclosed
US-20070142381-A1 Calcium receptor modulating agents AMGEN INC. 2007-06-21 — — US disclosed
US-20070072851-A1 Pyrazolopyridine and pyrazolopyrimidine compounds AMGEN INC. (US) 2007-03-29 — — US disclosed
US-20070072851-A1 Pyrazolopyridine and pyrazolopyrimidine compounds AMGEN INC. (US) 2007-03-29 — — US disclosed
US-20070072862-A1 Bis-aryl amide compounds and methods of use AMGEN INC. 2007-03-29 — — US disclosed
US-20070072862-A1 Bis-aryl amide compounds and methods of use AMGEN INC. 2007-03-29 — — US disclosed
US-7196102-B2 Calcium receptor modulating agents AMGEN INC. (US) 2007-03-27 — — US disclosed
US-7196102-B2 Calcium receptor modulating agents AMGEN INC. (US) 2007-03-27 — — US disclosed
US-7176322-B2 Calcium receptor modulating agents AMGEN INC. (US) 2007-02-13 — — US disclosed
US-7176322-B2 Calcium receptor modulating agents AMGEN INC. (US) 2007-02-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072862-A1 Bis-aryl amide compounds and methods of use LCK, BTK, IRAK1 NNMT 1923/4885CHRNB2 2871/4885CHRNA4 2226/4885
US-20230227442-A1 HETEROALKYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS SCN7A, TRPV1, SCNN1A NNMT 2784/4885CHRNB2 767/4885CHRNA4 493/4885
US-20230234948-A1 CYCLOPROPYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS TRPV1, SCN7A, TRPA1 NNMT 1628/4885CHRNB2 349/4885CHRNA4 192/4885
US-20070142381-A1 Calcium receptor modulating agents PTH1R, CASR, CALCR NNMT 3656/4885CHRNB2 1642/4885CHRNA4 1194/4885
US-11807634-B2 Cyclopropyl dihydroquinoline sulfonamide compounds TRPV1, SCN7A, TRPA1 NNMT 1561/4885CHRNB2 319/4885CHRNA4 166/4885
US-20070072851-A1 Pyrazolopyridine and pyrazolopyrimidine compounds LCK, MAP4K5, TPMT NNMT 1192/4885CHRNB2 4839/4885CHRNA4 4759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.